According to the FDA, Invokana does Increase the Risk of Osteoporosis. Invokana is a glifozin class drug that is prescribed by family doctors to treat Type II diabetes. Developed and manufactured by Mitsubishi Tanabe Pharma. The oral diabetes prescription medication has shown to be highly effective in controlling blood sugar levels by assisting the kidneys in ridding the body of glucose in the bloodstream. The drug marketers claim that with exercise and diet, Invokana can be highly effective at treating and controlling diabetes. As per a recent study it reveals that Invokana increase the risk of Osteoporosis, a disease where decreased bone strength increases the risk of a broken bone. It is the most common reason for a broken bone among the elderly. Bones that commonly break include the back bones, the bones of the forearm, and the hip. Until a broken bone occurs there are typically no symptoms. Bones may weaken to such a degree that a break may occur with minor stress or spontaneously. Chronic pain and a decreased ability to carry out normal activities may occur following a broken bone. Canagliflozin, a drug that is sold under brand names Invokamet and Invokana, has been known to cause ketoacidosis, kidney damage and heart attacks. Now, the US Food and Drug Administration (FDA) have released a further warning, stating that it also increases the risk of osteoporosis.
Clinical studies have demonstrated that elderly people who have type 2 diabetes and who were treated with canagliflozin for a period of two years or longer had higher levels of reduced bone density, particularly in their hips and lower spines. The recent studies show that treatment with Invokana can greatly accelerate the process. Some patients can suffer fractures in as little as three months after starting on the medication. The highest risk for both fractures and bone loss was experienced by post menopausal women. The research took two years to complete and it was part of a post marketing safety evaluation. More than 700 geriatric patients took part in the study.
According to a proclamation from the Food and Drug Administration (FDA) reported on September 10th, as per the additional data it’s confirm that fractures occur more frequently with canagliflozin [Invokana] than placebo. After starting the drug within 12 weeks fractures can occur. Additional data was gathered from nine other clinical trials in which test subjects took the drug for an average of 85 weeks. As a result of this new data, stronger warnings will be added to Invokana prescribing information. The FDA is advising physicians to consider the risk of bone fractures before prescribing Invokana for their diabetic patients.